WEBULL
WebtradeDownload

Will Hearing Glasses Launch Change EssilorLuxottica Stock's Narrative

Simply Wall St · 2d ago
  • EssilorLuxottica has launched Nuance Audio Plus, an FDA cleared line of invisible open ear hearing glasses for adults with perceived mild to moderate hearing loss, adding improved audio performance, longer battery life, call handling and more frame styles.
  • The product turns a regulated hearing device into everyday eyewear, widening EssilorLuxottica's reach into MedTech while using its strength in design, distribution and lens customization.
  • Next comes a look at how EssilorLuxottica's investment narrative interacts with Nuance Audio Plus, particularly its integrated hearing and vision focus.
Spot fresh potential by lining up EssilorLuxottica against a curated group of resilient, MedTech adjacent businesses using our list of solid balance sheet and fundamentals (204 results).

EssilorLuxottica Société anonyme Investment Narrative Recap

To own EssilorLuxottica Société anonyme, you need to believe that its mix of premium eyewear, MedTech and direct channels can keep pulling in steady demand even as competition in smart and medical devices rises. The Nuance Audio Plus launch fits that story, but in the near term the key swing factor still looks like execution on higher value products without further margin pressure from costs.

The main operational risk right now is that wearables and MedTech skew toward lower profitability while inflation and tariffs keep squeezing gross margins. Nuance Audio Plus does not radically change that picture. It reinforces the MedTech push, which could support pricing power, yet it also adds complexity in R&D, marketing and after sales support.

The Nuance Audio Plus announcement is the clearest recent example of EssilorLuxottica Société anonyme leaning into hearing and vision as a combined health platform. This sits alongside existing projects in myopia management and smart eyewear and gives the group another way to shift its mix toward higher priced devices that extend beyond simple frames and lenses.

For catalysts, successful adoption of Nuance Audio Plus would support the broader thesis of growth from advanced MedTech. However, slow uptake or returns below expectations would feed into the margin dilution concerns already flagged around wearables. Execution around distribution, customer education and aftercare will be critical, since missteps there could blunt both revenue potential and profitability.

EssilorLuxottica earnings and revenue expectations behind Nuance Audio Plus

EssilorLuxottica Société anonyme's Nuance Audio Plus launch is dropping into a story that already assumes meaningful expansion in both sales and profit. Analysts are pencilling in 7.6% yearly revenue growth over the next few years, higher profit margins and a bigger earnings base by the end of this decade.

Those forecasts rest on a move from €2.5b in earnings today to €3.8b by 2029, with the most optimistic projections reaching €4.7b. That shift implies earnings rising by about €1.3b on the consensus view, which is a sizeable jump in absolute profit before any benefit from share count reduction.

Assumptions also extend to profitability and valuation. Profit margins are expected to move from 8.5% to 10.3% over roughly three years, while the stock would need to command a P/E of 34.2x on 2029 earnings, compared with 26.8x today and 23.3x for the wider GB medical equipment peer group. Nuance Audio Plus sits inside that narrative as one more MedTech layer rather than the sole growth engine.

On the top line, consensus numbers point to revenues of €36.5b and earnings of €3.8b by 2029. For that outlook to hold, the business would need to sustain 7.6% annual revenue growth and lift earnings from €2.5b today by roughly €1.3b by the 2029 estimate year.

Uncover why EssilorLuxottica Société anonyme's fair value indicates a 59% potential upside to its current price that could narrow quickly.

ENXTPA:EL 1-Year Stock Price Chart
ENXTPA:EL 1-Year Stock Price Chart

Exploring Other Perspectives

Some of the most optimistic analysts already describe EssilorLuxottica as a MedTech platform in the making, with some counting on revenue reaching about €39.6b and earnings of €4.7b by 2029. Those views lean heavily on smart eyewear and diagnostics as key engines. The Nuance Audio Plus launch may lead you to revisit how far that story could stretch or, if you are more cautious, whether those expectations feel too rich. Either way, use the spread between the bullish and baseline numbers as a reminder that opinions differ widely and explore both sets of assumptions before deciding where you stand.

Explore 7 other EssilorLuxottica Société anonyme fair value estimates, including one that suggests up to 128% upside from the current price.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis carefully.

Looking For More Investment Ideas Beyond EssilorLuxottica?

EssilorLuxottica Société anonyme might be central to your current thinking, yet it rarely pays to focus on a single stock. If you want to pressure test your thesis and find other businesses with robust fundamentals, the Simply Wall St Screener can help you line up comparable opportunities quickly.

  • Prefer steadier profiles with an emphasis on financial resilience and strong balance sheets? Use the 222 resilient stocks with low risk scores to spot companies that may better match that preference.
  • If you want potential mispricings filtered for quality as well as valuation, the 174 high quality undervalued stocks can surface ideas where fundamentals and pricing appear out of sync.
  • For investors who care about income as much as price moves, the 223 dividend fortresses can highlight higher yielding stocks that still meet key quality checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.